Expression and Functions of the Vascular Endothelial Growth Factors and Their Receptors in Human Basophils

Amato de Paulis, Nella Prevete, Isabella Fiorentino, Francesca Wanda Rossi, Stefania Staibano, Nunzia Montuori, Pia Ragno, Amelia Longobardi, Bianca Liccardo, Arturo Genovese, Domenico Ribatti, Andrew F. Walls and Gianni Marone

*J Immunol* 2006; 177:7322-7331; doi: 10.4049/jimmunol.177.10.7322

http://www.jimmunol.org/content/177/10/7322

References

This article cites 64 articles, 26 of which you can access for free at:
http://www.jimmunol.org/content/177/10/7322.full#ref-list-1

Subscription

Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions

Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts

Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Expression and Functions of the Vascular Endothelial Growth Factors and Their Receptors in Human Basophils

Amato de Paulis,* Nella Prevete,* Isabella Fiorentino,* Francesca Wanda Rossi,* Stefania Staibano,† Nunzia Montuori,‡ Pia Raggio,‡ Amelia Longobardi,* Bianca Liccardo,* Arturo Genovese,* Domenico Ribatti,§ Andrew F. Walls,‖ and Gianni Marone2*

Angiogenesis is a multistep complex phenomenon critical for several inflammatory and neoplastic disorders. Basophils, normally confined to peripheral blood, can infiltrate the sites of chronic inflammation. In an attempt to obtain insights into the mechanism(s) underlying human basophil chemotaxis and its role in inflammation, we have characterized the expression and function of vascular endothelial growth factors (VEGFs) and their receptors in these cells. Basophils express mRNA for three isoforms of VEGF-A (121, 165, and 189) and two isoforms of VEGF-B (167 and 186). Peripheral blood and basophils in nasal polyps contain VEGF-A localized in secretory granules. The concentration of VEGF-A in basophils was 144.4 ± 10.8 pg/10^6 cells. Immune activation of basophils induced the release of VEGF-A. VEGF-A (10–500 ng/ml) induced basophil chemotaxis. Supernatants of activated basophils induced an angiogenic response in the chick embryo chorioallantoic membrane that was inhibited by an anti-VEGF-A Ab. The tyrosine kinase VEGFR-2 (VEGFR-2/KDR) mRNA was expressed in basophils. These cells also expressed mRNA for the soluble form of VEGFR-1 and neuropilin (NRP)1 and NRP2. Flow cytometric analysis indicated that basophils express epitopes recognized by mAbs against the extracellular domains of VEGFR-2, NRP1, and NRP2. Our data suggest that basophils could play a role in angiogenesis and inflammation through the expression of several forms of VEGF and their receptors. The Journal of Immunology, 2006, 177: 7322–7331.

Copyright © 2006 by The American Association of Immunologists, Inc. 0022-1767/06/$02.00
Materials and Methods

Reagents

The following reagents were used: 60% HClO4 (Baker Chemical); human serum albumin (HSA), PIPES, protease inhibitors, cycloheximide, and anti-VEGF-2/2-KDR mAb (Sigma-Aldrich); HBSS, FCS, and RNease-4PCR (Ambion); Superscript III and TRizol reagent (Invitrogen Life Technologies); RPMI 1640 (Invitrogen Life Technologies) with 25 mM HEPES buffer and Eagle’s MEM (Flow Laboratories); Dextran 70 and Percoll (Pharmacia Fine Chemicals); HRP-conjugated anti-mouse IgG (Amersham Biosciences) and protein colorimetric assay (Bio-Rad); anti-VEGF-2/KDR mAb (Sigma-Aldrich) and FITC- and PE-labeled anti-IgE Abs (Caltag Laboratories); PE-labeled anti-VEGF-2/2-KDR mAb, VEGF-A165 and VEGF-A121, and polyclonal anti-human VEGF-A (R&D Systems); human recombinant VEGF-A and VEGF-B (R&D Systems); sVEGFR-1 (R&D Systems); human recombinant NRP1 and NRP2. Basophils were purified from the peripheral blood of healthy volunteers, aged from 20 to 39 years, negative for HIV-1, HIV-2, hepatitis C virus, and hepatitis B virus Abs. Buffy coat cell packs were provided by the Immunology Service (University of Naples Federico II). Informed consent, according to the guidelines of the University of Naples Federico II institutional review board for the use of humans in research, was obtained. Cells were reconstituted in PBS containing 0.5 g/L HSA and 3.42 g/L sodium citrate and loaded onto a Percoll gradient. Basophils were further purified to near homogeneity (99%) by depleting B cells, monocytes, NK cells, dendritic cells, erythrocytes, platelets, neutrophils, eosinophils and T cells, using a mixture of hapten-conjugated CD3, CD7, CD14, CD15, CD16, CD36, CD45RA, and anti-HLA-DR Abs and MACS MicroBeads coupled to an anti-hapten mAb (26). The magnetically labeled cells were depleted by retaining them on a MACS column in the magnetic field of the MidiMACS (Miltenyi Biotec). Yields ranged from 3 x 10^6 to 10^7 basophils with purity >99%, assessed by basophil staining with Alcian blue, and counting in a Spiers-Levy eosinophyl counter (26).

Flow cytometric analysis of surface molecules

Flow cytometric analysis of cell surface molecules was performed as described previously (27). Briefly, after saturation of nonspecific binding sites with total rabbit IgG, cells were incubated for 20 min at +4°C with specific or isotype control Abs. For indirect staining, this step was followed by a second incubation for 20 min at +4°C with an appropriate anti-isotype-conjugated Ab. Finally, cells were washed and analyzed with a FACSCalibur Cytofluorometer using CellQuest software (BD Biosciences). A total of 10^4 events for each sample was acquired in all cytometer measurements.

Reverse transcriptase-PCR

Total cellular RNA was isolated by RNease-4PCR (Ambion) or TRizol reagent (Invitrogen Life Technologies), according to the supplier’s protocol. Total RNA was quantitated spectrophotometrically, and 1 μg of total RNA was reversely transcribed with random hexamer primers and 200 U of Superscript III Reverse Transcriptase (Invitrogen Life Technologies) (27). Two microliers of reversely transcribed DNA was then amplified, using VEGF-A121,165-specific 5’ sense (GTGGAATGCAGACCAAA GAAAG) and 3’ antisense (AAACCCCGAGGACACAGCCT) primers, VEGF-A165-specific 5’ sense (GTATAAGCTTCAAGGCCGTG) and 3’ antisense (VACCCTCGAGAAGACACAGC) primers, VEGF-B-specific 5’ sense (GTGGAATGCAGACCAAA GAAAG) and 3’ antisense (GCTCATGTT GACCTTTGCGA) primers, VEGF-C-specific 5’ sense (ATGTTTCTCCG GATGCTGGA) and 3’ antisense (CATTGGGTGGAAGAGATTG) primers, VEGF-D-specific 5’ sense (GTGATGTCCTCTGCTGCGACG) and 3’ antisense (AGGCTCTTCCTTACGACACG) primers, VEGF-R2-specific 5’ sense (GCCATGTGT ATTGCTTCCTCACC) and 3’ antisense (CTGGAAGATCCCTTCTGTG) primers, VEGF-specific 5’ sense (CCTCGCAACAAACGGAAGAAG) and 3’ antisense (GAATGCACTGATGACCAAGC) primers, and GAPDH-specific 5’ sense (GCCAGGATTACTCCTCTC) and 3’ antisense (GAGGCAAGGATGATGTC) primers. A total of two sets of primers were used for VEGF-1/1-F:1-1: specific 5’ sense (ATCAGATGATCG GAAGACCC) and 3’ antisense (GGAAATCTCATCTGTTTGC) primers; and 2 specific 5’ sense (CTTGAGAAGATTCTTCTCT) and 3’ antisense (GGTAAATACATCTGTTCT) primers. The reaction products were analyzed by electrophoresis in 1% agarose gel containing ethidium bromide, followed by photography under UV illumination (27).

Chemotaxis assay

Modified Boyden chambers were used for chemotaxis assays. Twenty-five microliters of PACGM buffer with or without the indicated concentrations of chemoattractants were loaded in the lower compartments of a 48-well microchemotaxis chamber (NeuroProbe). The lower compartments were covered with 0.5-μm pore polyvinylpyrrolidone-free polycarbonate membranes. Thirty microliters of the cell suspension (5 x 10^6/well), resuspended in PACGM, was pipetted in the upper compartment. The chemotaxis chamber was incubated for 1 h at 37°C in a humidified chamber [5% CO2 (Automatic CO2 Incubator, model 160IR; ICN Flow)]. At the end of incubation, the membrane was removed; the upper side was washed with PBS, and the filter was fixed, stained with May-Grunwald/Giemsa, and mounted on a microscope slide with Cytoseal (Stephen Scientific). Basophil chemotaxis was quantitated microscopically by counting the number of cells attached to the surface of a 5-μm pore polycarbonate membrane. In each experiment, 10 fields per triplicate filter were measured at a magnification of x40. The results were compared with buffer controls. Checkboard analysis was used to discriminate chemotaxis and nondirect migration (chemokinesis) of basophils. In these experiments, basophils were placed in the upper chemotactic chambers, and various concentrations of stimuli or buffer were added to the upper or lower wells or to both. Chemotactic (chemokinesis) was determined in the absence of chemoattractants or when stimuli were added to either the lower or upper chambers.

Histamine release

Basophils (~6 x 10^6 basophils/tube) were resuspended in PCG, and 0.1 ml of the cell suspension was placed in 12 x 75-mm polyethylene tubes (Sarstedt) and warmed to 37°C. 0.1 ml of each prewarmed releasing stimulus was added, and incubation was continued at 37°C (25). The reactions were stopped by the addition of 2 ml of cold methanesulfonic acid and the cell-free supernatant was assayed for histamine content with an automated fluorometric technique (29). Total histamine content was assessed by lysis induced by incubating the cells with 2% HClO4 before centrifugation. To
calculate histamine release as a percentage of total cellular histamine. The spontaneous release of histamine from basophils (2–12% of the total cellular histamine) was subtracted from both the numerator and denominator (25). All values are based on the means of duplicate determinations. Replicates differed in histamine content by <10%.

**VEGF-A ELISA**

VEGF-A release in the culture supernatants of basophils was measured in duplicate determinations with a commercially available ELISA (R&D Systems).

**Chick embryo chorioallantoic membrane assay**

Fertilized White Leghorn chicken eggs were incubated under constant humidity at 37°C (30). On the third day of incubation, a square window was opened in the shell after removal of 2–3 ml of albumen so as to detach the developing CAMs from the shell. The window was sealed with a glass of the same dimension, and the eggs were returned to the incubator. CAMs were treated at day 8 with supernatants of anti-IgE-activated (0.3 μg/ml) basophils dissolved in 3 μl of DMEM and adsorbed on 1-mm² sterilized gelatin sponges (Gelfoam; Upjohn). Sponges containing vehicle alone were used as negative controls, whereas sponges containing 500 ng/embryo of human recombinant VEGF-A (R&D Systems) were used as positive controls. In some experiments, supernatants of anti-IgE-activated basophils were preincubated with polyclonal goat anti-VEGF-A-neutralizing Ab (500 ng/embryo) (R&D Systems) or with the isotype control goat IgG (500 ng/ml) (Chemicon International) before implantation. CAMs were examined daily until day 12 and photographed in ovo with a stereomicroscope SR equipped with the MC163 Camera System. Blood vessels entering the sponge within the focal plane of the CAM were counted by two observers in a double-blind fashion at ×50 magnification.

**Double-immunofluorescence staining on cytospin**

Basophils purified as previously described were left to adhere on glass precoated with 1% poly-l-lysine (Menzel-Glaser) for 1 h at 22°C. Then cells were fixed in 4% paraformaldehyde. Nonspecific bonds were blocked by preincubating fixed basophils with nonimmune normal horse serum (Vector Laboratories) for 30 min at 22°C (31). Double-immunofluorescence staining was performed by incubation overnight at 4°C with the primary Abs BB1 (1/100) and rabbit polyclonal anti-VEGF-A (1/300) (A-20; Santa Cruz Biotechnology). Cells were then incubated with FITC-conjugated rabbit anti-mouse secondary Ab, (DakoCytomation) (1/50) for 1 h at 22°C and with TRITC-conjugated swine anti-rabbit secondary Ab (DakoCytomation) (1/50) for 1 h at 22°C. The nuclear counterstaining was performed with 4',6'-diamidino-2-phenylindole (Roche) for 15 min at 22°C. Finally, the glasses were mounted with coverslips using a synthetic mounting medium (DakoCytomation). Basophils were observed under a Zeiss Axiosvert 100 M microscope adapted with a LSM 510 confocal system. Images were recorded with LSM 510 software (Zeiss) and exported as a JPG.

**Double-immunofluorescence staining on cryostat sections of nasal polyps**

Nasal polyp specimens were obtained from patients undergoing polypectomy. These patients did not assume anti-inflammatory steroids for at least 15 days before surgery. Surgically removed specimens were immediately frozen at −25°C, and 5-μm-thick cryostat sections were cut from frozen tissue blocks by a motor-driven cryostat (31). Sections were picked up on clean glass slides, fixed in acetone for 10 min at 22°C, and stored at −25°C until use. Nonspecific bonds were blocked by preincubating fixed tissue with nonimmune normal horse serum (Vector Laboratories) for 30 min at 22°C. Double-immunofluorescence staining was performed by incubation overnight at 4°C with the primary Abs BB1 (1/100) and rabbit polyclonal anti-VEGF-A (1/300) (A-20; Santa Cruz Biotechnology). Sections were then incubated with FITC-conjugated rabbit anti-mouse secondary Ab (DakoCytomation) (1/50) for 1 h at 22°C and with TRITC-conjugated swine anti-rabbit secondary Ab (DakoCytomation) (1/50) for 1 h at 22°C. The nuclear counterstaining was performed with 4',6'-diamidino-2-phenylindole (Roche) for 15 min at 22°C. Finally, the glasses were mounted with coverslips using the Dako fluorescent mounting medium. Sections were analyzed under a Zeiss Axiosvert 100 M microscope adapted with a LSM 510 confocal system. Images were recorded with LSM 510 software (Zeiss) and exported as a JPG.

**Lactate dehydrogenase assay**

Lactate dehydrogenase release at the end of the incubations served as an index of cytotoxicity. It was measured in cell-free supernatants using a commercially available kit (Sigma-Aldrich) (27).

**FIGURE 1.** Expression of different forms of VEGF mRNA in human basophils. Purified basophils were lysed in lysis buffer to obtain a total RNA preparation. Total RNA was reverse-transcribed and amplified by 40 PCR cycles in the presence of VEGF-specific primers and of GAPDH primers as loading control. PCR amplification of buffer represented the negative control. PCR products were analyzed by electrophoresis in 1% agarose gel containing ethidium bromide, followed by photography under UV illumination.

**Results**

**Expression of mRNA for the components of the VEGF family in human basophils**

The human VEGF-A gene encodes major peptides of 189, 165, and 121 aa as a result of alternative splicing. VEGF-A165, the predominant isoform in several normal and tumor cells, lacks the residues encoded by exons 6, whereas VEGF-A121 lacks the residues encoded by exons 6 and 7 (2). We investigated the expression of VEGF mRNA in basophils purified (>99%) from peripheral blood of normal donors. The analysis of PCR products by electrophoresis in agarose gel revealed three VEGF-A isoforms (VEGF-A121, VEGF-A165, and VEGF-A189) and two VEGF-B isoforms (VEGF-B167 and VEGF-B166) (Fig. 1). By contrast, VEGF-C and VEGF-D mRNA, two angiogenic mediators of lymphatic development (8), were not detected in human basophils.

**Detection of VEGF-A in human basophils**

We then investigated VEGF-A expression in basophils at protein level. Basophils were lysed in 1% Triton X-100/PBS in the presence of protease inhibitors, and the total content of immunoreactive VEGF-A was measured by specific ELISA. In a series of eight experiments, the concentration of VEGF-A in basophils ranged from 50 to 160 pg/10⁶ basophils with a mean value of 144 ± 10.8 pg/10⁶ cells.

**Localization of VEGF-A in human peripheral blood basophils**

To verify the intracellular localization of VEGF-A, we analyzed cytospins of enriched preparations of peripheral blood basophils by confocal microscopy. We used a mAb BB1 that specifically recognizes basogranulin in secretory granules of human basophils but not in neutrophils, lymphocytes, and monocytes (22, 33). We also used a rabbit polyclonal Ab raised against aa 1–140 of human VEGF-A. Fig. 2A shows the localization of basogranulin in secretory granules of the cells. Fig. 2B shows the localization of VEGF-A in the cytoplasm of basophils. Last, Fig. 2C shows the colocalization of BB1⁺ secretory granules with VEGF-A immunoreactivity. Staining of basophils with irrelevant isotype controls was negative (data not shown). Similar results were obtained in 10
additional preparations of basophils purified from peripheral blood of healthy volunteers. These results are compatible with the hypothesis that VEGF-A is stored in secretory granules of peripheral blood basophils.

Localization of VEGF-A in basophils in nasal polyps

Nasal polyps are characterized by hyperplasia of the mucosal epithelium and submucosal mucous glands with underlying areas of infiltrating inflammatory cells and proliferating blood vessels (34). VEGF and its receptors have been implicated in nasal polyposis (35). Nasal polyp tissues obtained from four patients undergoing polypectomy were examined by immunohistochemistry using the mAb BB1 that specifically recognizes human basophils also in tissue (22, 33) and a rabbit polyclonal anti-VEGF-A. Fig. 3 shows BB1+ basophils in the perivascular area. These cells stained positive also for VEGF-A. Fig. 3 also shows the colocalization of BB1 and VEGF-A. Staining of tissues with irrelevant isotype controls was negative. No basophils were detected in normal nasal mucosa obtained from the middle turbinate (data not shown).

Kinetics of VEGF-A and histamine release from human basophils

In a series of five experiments, we evaluated the kinetics of VEGF-A and histamine release in unstimulated basophils and in cells immunologically activated with anti-IgE. Basophils activated with anti-IgE rapidly released histamine, which peaked at 30 min. Fig. 4 shows that stimulation of basophils with anti-IgE caused a small increase in VEGF-A secretion that was detectable after 30 min. The release of VEGF-A induced by anti-IgE reached a plateau after 2 h of incubation and remained stable up to 4 h. Basophils kept in culture for up to 3–4 h had a small spontaneous release of histamine (~10%) and of VEGF-A (~20 pg/10^6 basophils).

The release of VEGF-A induced by anti-IgE from basophils that required hours of incubation suggested that protein synthesis may be necessary for this phase. Thus, we examined the effect of cycloheximide (protein synthesis inhibitor) on both the early (30 min) and late (2 h) release of VEGF-A induced by anti-IgE. In three experiments, preincubation (30 min) of basophils with cycloheximide (10 μM) did not modify the early (30 min) release of VEGF-A induced by anti-IgE (24.7 ± 2.0 vs 25.3 ± 3.4 pg/10^6 basophils). In contrast, the production of VEGF-A after 2 h of incubation with anti-IgE was reduced significantly by cycloheximide (58.0 ± 3.7 vs 34.3 ± 4.7 pg/10^6 basophils; p < 0.01). Cycloheximide did not affect basophils viability (data not shown).

Recently, Abdel-Majid and Marshall (36) demonstrated that PGE_2 is a potent inducer of VEGF-A secretion by human mast cells. Therefore, in three experiments, we investigated the possibility that a wide spectrum of PGE_2 concentrations (10^-9–10^-5 M) induces the release of VEGF-A from human basophils. In none of these experiments did PGE_2 cause the release of VEGF-A (data not shown).

Expression of mRNA for VEGFRs in human basophils

Two VEGFRs, VEGFR-1/Flt-1 and VEGFR-2/KDR, are expressed on endothelial cells (37) and on some immune cells (38-43). These VEGFRs are structurally highly homologous; however, their biochemical features are quite distinct. Although VEGFR-1/Flt-1 has a greater affinity for VEGF-A, VEGFR-2/KDR is tyrosine-phosphorylated more efficiently upon ligand binding (44). A soluble truncated form of VEGFR-1 (sVEGFR-1) that contains only the first six Ig-like domains (12) binds to VEGF-A as strongly as does full-length VEGFR-1 and inhibits VEGF-A activity by sequestering it from signaling receptors and by forming nonsignaling heterodimers with VEGFR-2. We analyzed the mRNA expression of VEGFR-1/Flt-1, VEGFR-2/KDR, and sVEGFR-1 in human basophils. Fig. 5A shows the results of a typical experiment demonstrating that VEGFR-2/KDR, but not VEGFR-1/Flt-1, is expressed in basophils. Interestingly, basophils also constitutively expressed sVEGFR-1. Similar results were obtained in seven experiments using mRNA purified from basophils of different donors. In other experiments, we used two different sets of primers to identify VEGFR-1/Flt-1 mRNA in basophils (see Materials and Methods). As a positive control, we used human polymorphonuclear cells (PMNs) and PBMCs that express VEGFR-1/Flt-1 (38, 39, 41, 43). Fig. 5B shows the results of one of three typical experiments demonstrating that VEGFR-1/Flt-1 was expressed in both PMNs and PBMCs but not in basophils.
Expression of mRNA for NRP1 and NRP2 in human basophils

Both NRP1 and NRP2 are expressed by endothelial cells (45, 46). Increasing evidence suggests that NRPs are required to initiate immune responses. For instance, NRP1 expression is observed in human CD4^+CD25^+ Treg cells (47) and rodent B lymphocytes, monocytes (19), T cells, and dendritic cells (40). Fig. 6 shows the result of a typical experiment demonstrating that NRP1 and NRP2 mRNA were expressed in basophils. Similar results were obtained in two experiments using mRNA purified from basophils of different donors.

Flow cytometry of VEGFR-2/KDR, NRP1, and NRP2 expression on human basophils

We then investigated the expression of VEGFRs at protein level by flow cytometry. Purified basophils (>99%) were incubated with a PE-labeled anti-VEGFR-2/KDR mAb and a FITC-labeled anti-IgE mAb or with purified control IgG. The results presented in Fig. 7 indicate that the vast majority (>80%) of peripheral basophils express on their surface epitopes recognized by a mAb against the extracellular domains of VEGFR-2. Fig. 8 shows that NRP1 and NRP2 were expressed on the vast majority (>80%) of basophils of normal donors.

Effects of VEGF-A165 and VEGF-A121 on chemotaxis of human basophils

VEGF-A stimulates endothelial cell migration (48), and it is chemotactic for certain human immune cells (38, 39, 42, 43). We evaluated the in vitro effects of a wide range of concentrations (5–500 ng/ml) of VEGF-A165 on basophil chemotaxis. Fig. 9 shows the results of seven experiments demonstrating that low concentrations of VEGF-A165 stimulate basophil chemotaxis. Higher concentrations (500 ng/ml) were found to inhibit basophil chemotaxis.

FIGURE 4. Kinetics of VEGF-A and histamine release from human basophils. Basophils were incubated with buffer (spontaneous release) or with anti-IgE (0.3 µg/ml). At each time point, supernatants were collected and centrifuged (1000 × g, 4°C, 5 min). The release of VEGF-A from basophils induced by anti-IgE is indicated by ○. The release of histamine from basophils induced by anti-IgE is indicated by □. VEGF-A and histamine release in the supernatants were determined by ELISA and fluorometric techniques, respectively. The values are expressed as the mean ± SEM of five experiments.

FIGURE 5. A, Expression of VEGFR mRNA in human basophils. Purified basophils were lysed in lysis buffer to obtain a total RNA preparation. Total RNA was reverse-transcribed and amplified by 40 PCR cycles in the presence of VEGFR-1/Flt-1-, VEGFR-2/KDR-, and sVEGFR-1-specific primers and GAPDH primers as loading control. PCR amplification of buffer represented the negative control. PCR products were analyzed by electrophoresis in 1% agarose gel containing ethidium bromide, followed by photography under UV illumination. B, Expression of VEGFR1/Flt-1 receptor mRNA in human basophils, PMNs, and PBMCs. Purified basophils, PMNs, or PBMCs were lysed in TRizol reagent to obtain a total RNA preparation. Total RNA was reverse-transcribed and amplified by 40 PCR cycles in the presence of two sets of specific VEGFR-1/Flt-1 primers and GAPDH primers as loading control. PCR amplification of buffer represented the negative controls. Lanes 1 and 2 represent the results obtained with primers 1 or primers 2 for VEGFR-1/Flt-1 (see Materials and Methods). Lane 3 represents results obtained with primers for GAPDH. PCR products were analyzed by electrophoresis in 1% agarose gel containing ethidium bromide, followed by photography under UV illumination.

FIGURE 6. Expression of NRP1 and NRP2 mRNA in human basophils (B). Purified basophils were lysed in TRizol reagent to obtain a total RNA preparation. Total RNA was reverse-transcribed and amplified by 40 PCR cycles in the presence of NRP1- and NRP2-specific primers and GAPDH primers as loading control. PCR amplification of buffer represented the negative controls (□). PCR products were analyzed by electrophoresis in 1% agarose gel containing ethidium bromide, followed by photography under UV illumination.

FIGURE 7. Cytofluorimetric analysis of VEGFR2/KDR expression by human basophils. Basophils were incubated (4°C, 20 min) with monoclonal anti-VEGFR-2/KDR PE-labeled and anti-IgE FITC-labeled (B) or isotype-matched Abs (A).
concentrations of VEGF-A165 caused basophil chemotaxis, which reached a plateau at 250 ng/ml.

As we demonstrate in this study, human basophils express mRNA for VEGF-A165 and VEGF-A121. Unlike VEGF-A165, VEGF-A121 does not express exon 7 (2). Although these two VEGF-A are both capable of activating VEGFR-1 and VEGFR-2, their potency in inducing biological activities is markedly different (49). When we compared the effects of increasing concentrations of VEGF-A165 and VEGF-A121 on human basophil chemotaxis, we found that the potency of VEGF-A121 was significantly lower than VEGF-A165 (Fig. 9).

We did a checkerboard analysis to determine whether VEGF-A165-induced migration of basophils resulted from chemotaxis or chemokinesis. We found that VEGF-A165 concentration-dependently induced the migration of basophils when added to the lower wells of the chemotaxis chamber. An optimal concentration of VEGF-A165 (250 ng/ml) added to cells in the upper wells or to both compartments did not induce directional basophil migration (data not shown). Thus, VEGF-A-induced migration of basophils resulted from chemotaxis rather than from chemokinesis.

FIGURE 8. Cytofluorimetric analysis of NRP1 and NRP2 expression by human basophils. Basophils were incubated (4°C, 20 min) with monoclonal anti-NRP1 (B), anti-NRP2 (C), or isotype-matched Abs (A). Cells were stained (4°C, 20 min) with secondary Ab (FITC-conjugated goat anti-mouse).

FIGURE 9. Effects of increasing concentrations of VEGF-A165 and VEGF-A121 on human basophil chemotaxis. Basophils were allowed to migrate with the indicated concentrations of VEGF-A165 or VEGF-A121 for 1 h at 37°C in a humidified (5% CO2) incubator. Values are the mean ± SEM of six experiments with different basophil preparations. *, p < 0.001 when compared with the corresponding value of VEGF-A165 (paired Student’s t test). Bars are not indicated when they are graphically too small.

Effect of anti-VEGFR-2 Ab on basophil chemotaxis caused by VEGF-A165

To verify whether the basophil chemotaxis caused by VEGF-A was mediated by the activation of VEGFR-2/KDR, we used an Ab against this receptor in blocking experiments. Fig. 10 shows that preincubation of basophils with an anti-VEGFR-2/KDR mAb (1–10 μg/ml) dose-dependently inhibited VEGF-A-dependent basophil chemotaxis. Preincubation of basophils with an irrelevant isotype mAb (1–10 μg/ml) did not modify basophil chemotaxis.

FIGURE 10. Effects of preincubation of basophils with an anti-VEGFR-2/KDR Ab (1 and 10 μg/ml) or nonimmune mouse IgG (1 and 10 μg/ml) on VEGF-A165-induced chemotaxis. Basophils, preincubated (1 h at 37°C) with Abs, were allowed to migrate with the indicated concentration of VEGF-A for 1 h at 37°C in a humidified (5% CO2) incubator. Values are the mean ± SEM of three experiments with different basophil preparations. *, p < 0.01 when compared with cells stimulated with VEGF-A165 (Duncan’s test).
caused by VEGF-A. Thus, binding of VEGF-A to VEGFR-2/KDR appears to be a requirement for VEGF-A-mediated basophil chemotaxis.

**Heterologous desensitization between VEGF-A_{165} and eotaxin or Hp (2–20)**

Human basophils display a variety of membrane receptors whose engagement induces chemotaxis. We have demonstrated that the vast majority (~80%) of basophils express the chemokine CCR3 receptor, whose activation by eotaxin/CCL11 induces chemotaxis (28). Moreover, the *Helicobacter pylori*-derived peptide Hp (2–20) is a potent basophil chemoattractant, which exerts its effect through activation of formyl peptide receptor like-1 (FPRL1) and FPR like-2 (FPRL2) (23). Preincubation of basophils with high concentrations of the agonist is known to cause desensitization to a subsequent challenge with the same stimulus (23, 27). We examined the relationship between VEGF-A_{165} and eotaxin or Hp (2–20) by evaluating the effects of heterologous desensitization between these stimuli on basophil chemotaxis. Purified basophils were preincubated with buffer or with VEGF-A_{165} (500 ng/ml) or eotaxin (100 ng/ml) or Hp (2–20) (500 nM) in P-EDTA for 1 h at 37°C. At the end of incubation, cells were washed and suspended in PACGM. Fig. 11A shows the results of a typical experiment in which the response to VEGF-A_{165} (500 ng/ml) was abolished by preincubation with the homologous stimulus (500 ng/ml). When basophils were desensitized by preincubation with eotaxin or Hp (2–20), which exert their effects by activating specific CCR3 and FPRL1/2 receptors, respectively (23, 27, 28), the response to the heterologous stimulus VEGF-A_{165} was not affected. Similar results were obtained when basophils were challenged with a lower concentration (100 ng/ml) of VEGF-A_{165} (Fig. 11B).

**Effect of VEGF-A_{165} on histamine and cytokine release from human basophils**

We evaluated the effect of increasing concentrations of VEGF-A_{165} on histamine and cytokine (IL-4 and IL-13) release from basophils purified (>99%) from healthy individuals. In five experiments, VEGF-A_{165} (10–500 ng/ml) did not cause either histamine or cytokine release from basophils. In these experiments, anti-IgE (0.1 μg/ml) was a potent stimulus for the secretion of histamine and cytokines (IL-4 and IL-13) from basophils (data not shown). In three experiments, preincubation (1 h at 37°C) of basophils with VEGF-A_{165} (10–100 ng/ml) did not modify the release of histamine and cytokines caused by anti-IgE from basophils (data not shown).

**Basophil-derived VEGF induces an angiogenic response in the chick embryo CAM**

The results of the experiments reported above demonstrate that the two forms of VEGF-A synthesized by basophils (VEGF-A_{165} and VEGF-A_{121}) induce basophil chemotaxis in vitro. In three experiments, we next investigated the possibility that basophil supernatants of immunologically activated basophils can induce an angiogenic response in vivo. To this aim, we used the chick embryo CAM assay at day 8 of incubation implanted with gelatin sponges adsorbed with basophil supernatants. Sponges adsorbed with vehicle alone or with VEGF-A_{165} were used as negative and positive controls, respectively. At day 12 of incubation, macroscopic observations of the CAMs showed that supernatants of basophils activated with anti-IgE for 2 h induced an angiogenic response characterized by the presence of allantoic vessels spreading radially toward the sponge in a spoke-wheel pattern (number of vessels at the sponge-CAM boundary = 27 ± 4). A similar macroscopic angiogenic response was observed in the implants treated with 500 ng of VEGF-A_{165} (number of vessels at the sponge-CAM boundary = 30 ± 4). The number of vessels at the sponge-CAM boundary caused by supernatants of unstimulated basophils kept in culture for 2 h was 14 ± 3. No vascular reaction was detectable around the sponges treated with vehicle alone (number of vessels at the sponge-CAM boundary = 7 ± 2). To assess whether the angiogenic response induced by basophil supernatants was due in part to their content of VEGF-A, supernatants of anti-IgE-activated

![FIGURE 11](http://www.jimmunol.org/)

**A**. Effects of heterologous desensitization between VEGF-A_{165} and eotaxin or Hp (2–20) on basophil chemotaxis. Basophils were incubated in PIPES buffer containing EDTA (4 mM) or VEGF-A_{165} (500 ng/ml) or eotaxin (100 ng/ml) or Hp (2–20) (500 nM) for 30 min at 37°C. At the end of incubation, cells were washed (twice) and resuspended in PACGM and challenged with VEGF-A_{165} (500 ng/ml). Basophils were allowed to migrate for 1 h at 37°C in a humidified (5% CO2) incubator. Values are the mean ± SEM of three experiments with different basophil preparations. **B**. Effects of heterologous desensitization between VEGF-A_{165} and eotaxin or Hp (2–20) on basophil chemotaxis. Basophils were incubated in PIPES buffer containing EDTA (4 mM) or VEGF-A_{165} (100 ng/ml) or eotaxin (100 ng/ml) or Hp (2–20) (500 nM) for 30 min at 37°C. At the end of incubation, cells were washed (twice) and resuspended in PACGM and challenged with VEGF-A_{165} (100 ng/ml). Basophils were allowed to migrate for 1 h at 37°C in a humidified (5% CO2) incubator. Values are the mean ± SEM of three experiments with different basophil preparations. *p < 0.01 when compared with cells stimulated with VEGF-A_{165} (Duncan’s test).
A response in the chick embryo CAM. Chick embryo CAMs at day 8 of incubation were implanted with gelatin sponges adsorbed with buffer alone (A) or with supernatants of basophils activated with anti-IgE for 2 h (B). At day 12 of incubation, macroscopic examination of the CAMs showed that supernatants of anti-IgE-activated basophils induced an angiogenic response characterized by the presence of allantoic vessels spreading radially toward the sponge in a spoke-wheel pattern (B). Anti-VEGF-A Ab reduced the angiogenic response of anti-IgE-activated basophil supernatants (C). This experiment is representative of three experiments with similar results.

Basophils were preincubated with an anti-VEGF-A Ab and then added to the CAM. Anti-VEGF-A Ab reduced the angiogenic response of basophil supernatants (number of vessels at the sponge-CAM boundary = 11 ± 3; p < 0.001 vs anti-IgE-activated basophil supernatants) (Fig. 12). Incubation of the basophils with the isotype control did not affect this response (data not shown).

Discussion

The VEGF/VEGFR system is emerging as a fundamental regulator of angiogenesis and tissue remodeling in inflammatory and neoplastic disorders (1, 2). Increasing evidence suggests that this complex biological system can also modulate several aspects of immune and inflammatory reactions (3–5, 38, 40, 41). In this study, we have identified a new mechanism by which human basophils might influence angiogenesis and inflammation through the synthesis and immunologic release of various isoforms of VEGF. In addition, we demonstrate that two VEGF-A isoforms function as basophil chemoattractants, presumably by interacting with VEGFRs. This novel autocrine loop involves the expression of several components of the VEGF family and their receptors on basophils.

Basophils purified from healthy donors express mRNA for three major isoforms of VEGF-A (121, 165, and 189) and two isoforms of VEGF-B (167 and 186). Interestingly, VEGF-C and -D mRNA, two mediators of lymphatic development (8), were not detected in basophils. Therefore, basophils display a selective expression of certain members of the VEGF family. It is conceivable that other components of the VEGF family could be expressed under different experimental conditions (e.g., hypoxia) or in certain pathological situations (e.g., inflammation and neoplasia).

We also demonstrate that VEGF-A is contained in the cytoplasmic secretory granules of basophils. The relevance of this finding is supported by two observations. First, VEGF-A colocalized with the basogranulin selectively present in basophil secretory granules (22, 33). More importantly, VEGF-A was localized in basophils infiltrating the sites of inflammation of biopsies of patients with nasal polyps. Thus, VEGF-A appears to be present not only in peripheral blood but more importantly at sites of chronic inflammation. The latter observation emphasizes the possibility that VEGF-A synthesized and released from basophils plays a dual role in inflammatory angiogenesis. First, VEGF-A released from circulating basophils might activate VEGF receptors present on circulating endothelial cell precursors and immune cells; second, VEGF-A released from basophils infiltrating the sites of chronic inflammation might represent a local source of an important angiogenic and chemotactic factor.

We have found that VEGF-A is stored in secretory granules and that the immunologic release of this cytokine from basophils follows a biphasic pattern: rapid release (30 min) after the anti-IgE challenge and a second wave, 2–4 h after challenge. The first wave of release is probably due to the secretion of preformed VEGF-A because it is not inhibited by the protein synthesis inhibitor cycloheximide. The second wave of VEGF-A release presumably represents de novo synthesis because it is significantly inhibited by cycloheximide. Our results indicate that the kinetics of the immunologic release of VEGF-A by basophils differs from that of IL-13 synthesized by these cells. In fact, the IgE-mediated release of VEGF-A from basophils is rapid and reaches a plateau within 4 h. By contrast, the release of IL-13 from basophils reaches a plateau ~18 h after immunologic challenge (50–52). Interestingly, immunologically activated human basophils express a very restricted (namely IL-4 and IL-13) cytokine profile (51–53). VEGF-A is the latest addition to the series of cytokines synthesized by these immune cells.

In our experiments, we found that IgE cross-linking is a stimulus for the production of VEGF-A. Similarly, Ag and anti-IgE can induce the release of VEGF-A from mast cells (54). Abdel-Majid and Marshall (36) have demonstrated that PGE2 is a potent inducer of VEGF-A secretion from human mast cells. By contrast, we found that PGE2 did not induce the production of VEGF-A from human basophils. This adds to the long list of immunological and biochemical differences between these two types of immune cells (20).

Mast cells, basophils, and eosinophils are considered primary effector cells in allergic disorders (20, 55). It has been shown that human mast cells synthesize and release several isoforms of VEGF-A (36, 54, 56, 57). Also human eosinophils exert direct proangiogenic effects (58). In the present study, we demonstrate that circulating and tissue infiltrating basophils express and release VEGF-A. Taken together, these findings support the hypothesis that the release of angiogenic factors from primary effector cells of allergic inflammation could represent a relevant aspect of tissue remodeling in chronic allergic disorders.

An important finding of this study is that VEGF-A exerts an autocrine chemotactic effect on human basophils, presumably through the engagement of VEGFR-2/KDR, NR1P1, and NR2P2. In addition, it is conceivable that VEGF produced by other immune or neoplastic cells might contribute to basophil infiltration in a variety of chronic inflammatory and neoplastic disorders.

The expression of VEGFRs on immune cells is still under careful scrutiny. Most human monocytes express VEGFR-1/Flt-1 but not VEGFR-2/KDR, NR1P1, and NR2P2. In addition, it is conceivable that VEGF produced by other immune or neoplastic cells might contribute to basophil infiltration in a variety of chronic inflammatory and neoplastic disorders.

The expression of VEGFRs on immune cells is still under careful scrutiny. Most human monocytes express VEGFR-1/Flt-1 but not VEGFR-2/KDR, NR1P1, and NR2P2. In addition, it is conceivable that VEGF produced by other immune or neoplastic cells might contribute to basophil infiltration in a variety of chronic inflammatory and neoplastic disorders.

The expression of VEGFRs on immune cells is still under careful scrutiny. Most human monocytes express VEGFR-1/Flt-1 but not VEGFR-2/KDR, NR1P1, and NR2P2. In addition, it is conceivable that VEGF produced by other immune or neoplastic cells might contribute to basophil infiltration in a variety of chronic inflammatory and neoplastic disorders.
of the activation route for VEGF-A. We found that basophils pre-
incubated with VEGF-A were desensitized to a subsequent chal-
lenge with the homolog stimulus. In contrast, when basophils were
exposed to eotaxin, which binds to CCR3 (38), or to Hp (2–20),
which binds to FPRL1/FPRL2 (23), the chemotactic response to
VEGF-A was not affected. The results of these two groups of ex-
periments are consistent with the hypothesis that VEGF-A induces
basophil chemotaxia by activating VEGFR-2/KDR.

It appears that basophils, by expressing VEGF-2/KDR and not
VEGFR-1/Flt-1, differ from the vast majority of monocytes (38,
39, 41, 62), eosinophils (42), and neutrophils (43) that express
VEGFR-1/Flt-1, and not VEGFR-2/KDR. VEGFR-1/Flt-1 appears
to mediate chemotaxis in human monocytes (38, 39), neutrophils
(43), and eosinophils (42). Endothelial cells express both VEGFR-
1/Flt-1 and VEGFR-2/KDR (63), and whereas VEGFR-2/KDR ac-
tivates cellular signaling, VEGFR-1/Flt-1 acts as a trap to seques-
ter VEGF from VEGFR-2/KDR. Soluble VEGFR-1, synthesized
by GM-CSF-activated monocytes (41), also prevents VEGF from
activating VEGFR-1/Flt-1 and VEGFR-2 (on endothelial cells) by inhibiting dimerization of VEGFR. Interestingly, also
human basophils express mRNA for sVEGFR-1.

We have also found that most basophils express NRP1, a core-
ceptor for VEGF-A165 (18, 45), which enhances VEGF-2/KDR-
induced responses (19). We also found that basophils express
NRP2 mRNA and protein. NRP1 has no known enzymatic ac-
tivity and therefore participates in signal transduction events by
forming a complex with tyrosine kinase receptors. However,
there is evidence that NRP1 supports the autocrine functions of
VEGF in cells lacking VEGF-2 expression (64). This raises the
possibility that, in certain cells, NRP1 functions either alone
or in concert with other tyrosine kinase-linked receptors to
transduce VEGF signaling. It has been demonstrated that NRP1
on cells other than endothelial cells can induce angiogenesis
(19). Therefore, it is feasible that NRP1 highly expressed on
basophils can enhance angiogenesis even when VEGF is not
abundantly expressed.

The results of this study might have practical implications in
several inflammatory disorders in which basophils that infiltrate
sites of inflammation play a prominent role (21–23). In fact,
we found that basophils in peripheral blood and tissue are a source
of VEGF, which is the most potent angiogenic factor known so far.
The identification of VEGFR-2/KDR and NRP1 and NRP2 on ba-
sophils has revealed a novel autocrine loop. This finding raises the
possibility that basophils might modulate angiogenesis. Pharma-
cological manipulation of the VEGF/VEGFR network, which is
already showing promise in relation to neoplastic angiogenesis
(65), might also be effective in disorders associated with basophil
recruitment and activation.

Acknowledgments
We dedicate this article to Rita Levi Montalcini on the occasion of the 20th
anniversary of the Nobel Prize. We thank Grazia Perrico for her inspir-
ing comments and encouragement during these studies. We are indebted to
Dr. Gianluca De Rienzo for his input in some of the initial experiments and
Jean Gilder for her critical reading of the manuscript.

Disclosures
The authors have no financial conflict of interest.

References
  932–936.
  vascular endothelial growth factor isoforms and their receptors Flt-1, KDR,
  endothelial growth factor and its receptors and angiogenesis in bronchial asthma.
5. Chetta, A., A. Zanini, A. Foresi, M. Del Donno, A. Castagnaro, R. D’Ippolito,
  airway remodeling in asthma is reduced by high dose of fluticasone.
6. Senger, D. R., S. J. Galli, A. M. Dvorak, C. A. Perruzzi, V. S. Harvey, and
  H. F. Dvorak. 1983. Tumor cells secrete a vascular permeability factor that pro-
  and N. Ferrara. 1996. The carboxyl-terminal domain (111–165) of vascular endothelial


